| 2026-04-28 Filed 2026-04-28 | Behbahani Ali Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 1,925 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
| Open filing 0001193125-26-187305 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Behbahani Ali Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 2,706 | — | — | 0 | Indirect (I) See Note 2 | No | F1, F2 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
- F2 The Reporting Person is a trustee of the Ali Behbahani Revocable Trust Dated June 26, 2015 (the Behbahani Trust), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the 1934 Act, as amended, or otherwise of such portion of the securities held by the Behbahani Trust in which the Reporting Person has no pecuniary interest.
| Open filing 0001193125-26-187305 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Behbahani Ali Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (11,459) — exercise price 37.94 | Disposed (D) | 11,459 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001193125-26-187305 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Behbahani Ali Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (8,011) — exercise price 51.30 | Disposed (D) | 8,011 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001193125-26-187305 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Behbahani Ali Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (9,174) — exercise price 63.68 | Disposed (D) | 9,174 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001193125-26-187305 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Ware Olivia C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (36,806) — exercise price 7.61 | Disposed (D) | 36,806 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001663771-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Ware Olivia C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (11,459) — exercise price 37.94 | Disposed (D) | 11,459 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001663771-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Ware Olivia C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (8,011) — exercise price 51.30 | Disposed (D) | 8,011 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001663771-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Ware Olivia C Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (9,174) — exercise price 63.68 | Disposed (D) | 9,174 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001663771-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Patel Kavita Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (27,077) — exercise price 6.66 | Disposed (D) | 27,077 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001670683-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Patel Kavita Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (20,513) — exercise price 15 | Disposed (D) | 20,513 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001670683-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Patel Kavita Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (11,459) — exercise price 37.94 | Disposed (D) | 11,459 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001670683-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Patel Kavita Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (8,011) — exercise price 51.30 | Disposed (D) | 8,011 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001670683-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Patel Kavita Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (9,174) — exercise price 63.68 | Disposed (D) | 9,174 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001670683-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Galligan Andrew H Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 5,000 | — | — | 0 | Indirect (I) By trust | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
| Open filing 0001417976-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Galligan Andrew H Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (16,829) — exercise price 69.87 | Disposed (D) | 16,829 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001417976-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Galligan Andrew H Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,784) — exercise price 63.68 | Disposed (D) | 1,784 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001417976-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Carroll Jill Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 1,479,148 | — | — | 0 | Indirect (I) See Note 2 | No | F1, F2 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
- F2 The securities are directly held by SR One Capital Fund I Aggregator, LP (SR One Fund I Aggregator). SR One Capital Partners I, LP (SR One Partners I) serves as the general partner of SR One Fund I Aggregator. The Reporting Person is a partner of SR One Capital Management, LP (SR One Capital Management), an entity affiliated with SR One Fund I Aggregator, and a limited partner of SR One Partners I. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (Section 16), except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
| Open filing 0001193125-26-188029 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Carroll Jill Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (11,459) — exercise price 37.94 | Disposed (D) | 11,459 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001193125-26-188029 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Carroll Jill Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (8,011) — exercise price 51.30 | Disposed (D) | 8,011 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001193125-26-188029 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Carroll Jill Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (9,174) — exercise price 63.68 | Disposed (D) | 9,174 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001193125-26-188029 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 67,048 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 5,000 | — | — | 0 | Indirect (I) By foundation | No | F1, F2 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
- F2 Shares held by a a family charitable foundation, of which the Reporting Person serves as the President. The Reporting Person has voting and investment power over all securities owned by the foundation.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (40,205) — exercise price 8.66 | Disposed (D) | 40,205 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (32,500) — exercise price 19.97 | Disposed (D) | 32,500 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (70,796) — exercise price 31.03 | Disposed (D) | 70,796 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (94,596) — exercise price 56.15 | Disposed (D) | 94,596 | — | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Restricted Stock Unit — underlying Common Stock (20,496) | Disposed (D) | 20,496 | — | — | 0 | Direct (D) | No | F4, F5 - F4 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
- F5 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Restricted Stock Unit — underlying Common Stock (61,590) | Disposed (D) | 61,590 | — | — | 0 | Direct (D) | No | F4, F5 - F4 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
- F5 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Restricted Stock Unit — underlying Common Stock (88,542) | Disposed (D) | 88,542 | — | — | 0 | Direct (D) | No | F4, F5 - F4 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
- F5 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Performance-based Restricted Stock Unit — underlying Common Stock (59,028) | Acquired (A) | 59,028 | — | — | 59,028 | Direct (D) | No | F4, F5 - F4 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
- F5 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Gilson Michelle Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Performance-based Restricted Stock Unit — underlying Common Stock (59,028) | Disposed (D) | 59,028 | — | — | 0 | Direct (D) | No | F4, F5 - F4 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
- F5 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
| Open filing 0001930862-26-000008 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Lubner David Charles Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 21,659 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
| Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Lubner David Charles Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (13,626) — exercise price 6.83 | Disposed (D) | 13,626 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Lubner David Charles Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (59,405) — exercise price 6.28 | Disposed (D) | 59,405 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Lubner David Charles Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (31,794) — exercise price 6.66 | Disposed (D) | 31,794 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Lubner David Charles Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (61,538) — exercise price 15 | Disposed (D) | 61,538 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Lubner David Charles Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (11,459) — exercise price 37.94 | Disposed (D) | 11,459 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Lubner David Charles Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (8,011) — exercise price 51.30 | Disposed (D) | 8,011 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Lubner David Charles Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (9,174) — exercise price 63.68 | Disposed (D) | 9,174 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001572000-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Myers Kristin Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (16,829) — exercise price 69.87 | Disposed (D) | 16,829 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0002018445-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Myers Kristin Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (1,784) — exercise price 63.68 | Disposed (D) | 1,784 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026, by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent. Each outstanding Company stock option (Company Option), whether or not vested, and which had a per share exercise price less than $115 per share (the Closing Amount), was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0002018445-26-000002 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Heery Christopher Officer: CHIEF MEDICAL OFFICER | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 23,749 | — | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the Merger Agreement), by and among Arcellx, Inc. (Company), Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (Purchaser), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (Closing Amount), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the Merger), with Company surviving the Merger as a wholly owned subsidiary of Parent.
| Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Heery Christopher Officer: CHIEF MEDICAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (10,901) — exercise price 6.28 | Disposed (D) | 10,901 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Heery Christopher Officer: CHIEF MEDICAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (43,604) — exercise price 6.28 | Disposed (D) | 43,604 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Heery Christopher Officer: CHIEF MEDICAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (132,416) — exercise price 15 | Disposed (D) | 132,416 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Heery Christopher Officer: CHIEF MEDICAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (40,000) — exercise price 19.97 | Disposed (D) | 40,000 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Heery Christopher Officer: CHIEF MEDICAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (76,242) — exercise price 31.03 | Disposed (D) | 76,242 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Heery Christopher Officer: CHIEF MEDICAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Option (right to buy) — underlying Common Stock (60,096) — exercise price 56.15 | Disposed (D) | 60,096 | — | — | 0 | Direct (D) | No | F2 - F2 Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a Company Option), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
| Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row |
| 2026-04-28 Filed 2026-04-28 | Heery Christopher Officer: CHIEF MEDICAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Restricted Stock Unit — underlying Common Stock (13,021) | Disposed (D) | 13,021 | — | — | 0 | Direct (D) | No | F3, F4 - F3 Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
- F4 Pursuant to the Merger Agreement, each outstanding restricted stock unit (a Company RSU), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
| Open filing 0001789632-26-000010 Read from the filing’s XML Dispute this row |